Trial Information

Summary: The study is looking at the metabolic side effects of the new antipsychotic medications. Participants should be stable on one of the following medications: olanzapine (zyprexa), ziprasidone (geodon), risperidone (risperdal) or aripiprazole (abilify). Patient's medications won't be changed. The study involves 3 visits at the Palo Alto VA and Stanford Hospital.

Gaining Weight On Your Medication? Find Out Your Risk for Diabetes!

We are looking for Men and Women 25 to 66 years old, and... Overweight

Already taking one of these medications

• Olanzapine (Zyprexa®)
• Ziprasidone (Geodon®)
• Aripiprazole (Abilify®)
• Risperidone (Risperdal®)

Stanford University Medical Center and the Palo Alto VA under Dr. Gerald Reaven and Dr. Steven Lindley are seeking volunteers for a study on certain mediations and effects on risk for type 2 diabetes. Non-diabetic volunteers on one of the medications described above will receive a free medical examination, a cholesterol panel, and test to determine personal risk for diabetes and heart disease. This study offers $320 compensation for your time.

Call Lilla Nikolics for more information: 650-493-5000 x 67289

Patient Inclusion Criteria:

• 25 to 66 years old
• body mass index (BMI) >25 < 35 kg/m2
• on a stable dose of olanzapine, risperidone, ziprasidone or aripiprazole for at least 3 months.

Patient Exclusion Criteria:

• No medications that directly affect insulin-mediated glucose disposal
• No intense suicidal impulses/intent
• No alcohol or substance abuse for 3 months.
• No major medical problems, i.e., clinically unstable medical disorder or condition; cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other systemic disease that would, in the investigator's clinical judgment interfer with the endocrine measures obtained in this study.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.